Removing immune 'brake' improves CAR T-cell therapy for pediatric bone cancer
Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma. There is a great clinical need for new therapies for childhood osteosarcoma, for which there are very few effective treatments for relapsed disease. The approach improved the cells' ability to control…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
